ArticleFrontiers in microbiology2024
Kaempferol restores the susceptibility of ESBLs
Article in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Kaempferol: advances in biosynthesis, molecular mechanisms, and therapeutic applications.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Advances in Kaempferol: Extraction, Biosynthesis, and Application with Antibacterial Agents.Antibiotics (Basel, Switzerland) · 2025Review
- Polyphenols as Potential β-Lactamase Inhibitors: An Integrated Computational and Experimental Study.Molecules (Basel, Switzerland) · 2025Article
- The interactions of natural compounds with Escherichia coli motility, attachment, communication systems, and mature biofilm.Archives of microbiology · 2025Review
- Dihydromyricetin alleviates ETEC K88-induced intestinal inflammatory injury by inhibiting quorum sensing-related virulence factors.BMC microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The development of extended-spectrum-beta-lactamase (ESBLs) Methods: The synergistic effect of kaempferol and ceftiofur against ESBLs Results and discussion: Kaempferol with ceftiofur exerts synergistic antibacterial and bactericidal effects on ESBLs
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.